GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » StemRIM Inc (TSE:4599) » Definitions » EBIT

StemRIM (TSE:4599) EBIT : 円-2,018.82 Mil (TTM As of Jul. 2024)


View and export this data going back to 2019. Start your Free Trial

What is StemRIM EBIT?

StemRIM's earnings before interest and taxes (EBIT) for the three months ended in Jul. 2024 was 円-502.55 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jul. 2024 was 円-2,018.82 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. StemRIM's annualized ROC % for the quarter that ended in Jul. 2024 was -297.48%. StemRIM's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2024 was -303.38%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. StemRIM's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jul. 2024 was -16.92%.


StemRIM EBIT Historical Data

The historical data trend for StemRIM's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StemRIM EBIT Chart

StemRIM Annual Data
Trend Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
EBIT
Get a 7-Day Free Trial 361.33 -575.82 -1,946.08 170.27 -2,018.82

StemRIM Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -612.96 -466.24 -537.56 -512.48 -502.55

Competitive Comparison of StemRIM's EBIT

For the Biotechnology subindustry, StemRIM's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StemRIM's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, StemRIM's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where StemRIM's EV-to-EBIT falls into.



StemRIM EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-2,018.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


StemRIM  (TSE:4599) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

StemRIM's annualized ROC % for the quarter that ended in Jul. 2024 is calculated as:

ROC % (Q: Jul. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Apr. 2024 ) + Invested Capital (Q: Jul. 2024 ))/ count )
=-2095.796 * ( 1 - -0.12% )/( (779.942 + 630.803)/ 2 )
=-2098.3109552/705.3725
=-297.48 %

where

Invested Capital(Q: Apr. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9583.299 - 64.49 - ( 8738.867 - max(0, 93.605 - 9368.301+8738.867))
=779.942

Invested Capital(Q: Jul. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9080.415 - 39.163 - ( 8410.449 - max(0, 67.527 - 8877.489+8410.449))
=630.803

Note: The Operating Income data used here is four times the quarterly (Jul. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

StemRIM's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jul. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Apr. 2024  Q: Jul. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2010.188/( ( (194.4 + max(535.829, 0)) + (195.433 + max(399.513, 0)) )/ 2 )
=-2010.188/( ( 730.229 + 594.946 )/ 2 )
=-2010.188/662.5875
=-303.38 %

where Working Capital is:

Working Capital(Q: Apr. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 17.318 + 612.116) - (64.49 + 0 + 29.115)
=535.829

Working Capital(Q: Jul. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 29.334 + 437.706) - (39.163 + 0 + 28.364)
=399.513

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jul. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

StemRIM's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jul. 2024 )
=-2018.824/11929.841
=-16.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


StemRIM EBIT Related Terms

Thank you for viewing the detailed overview of StemRIM's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


StemRIM Business Description

Traded in Other Exchanges
N/A
Address
7-15 Ayato Bio Incubator 3rd floor, Ayato Asagi 7-chome, Prefecture Ibaraki City, Osaka, JPN, 567-0085
StemRIM Inc is a biotechnology company engaged in developing regeneration-guided medicines. The business activity of the group includes research, development, manufacture, and sales of pharmaceuticals and medical devices and products such as gene therapy that activate stem cells existing in the body and induce regeneration of damaged tissue.

StemRIM Headlines

No Headlines